ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NAS: IMGN) , a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • 15th Annual BIO CEO & Investor Conference
    9:00 am ET, February 12, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Citi 2013 Global Healthcare Conference
    11:05 am ET, February 25, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • 2013 RBC Capital Markets Global Healthcare Conference
    10:30 am ET, February 26, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Cowen and Company 33 rd Annual Health Care Conference
    10:00 am ET, March 5, 2013 in Boston, MA
    Presenter: Gregory Perry, Executive Vice President and CFO

The webcasts will be accessible live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.


The Company is also participating in the Credit Suisse One-on-One Healthcare Conference March 5-6, 2013 in London, England.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP technology together with the Company's expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells. Ten TAP compounds are now in clinical testing, of which three are wholly owned by the Company. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, are under review in the US and Europe. Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.



For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:

The article ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Forex for Beginners

Learn about trading currencies and foreign exchange transactions

View Course »

Add a Comment

*0 / 3000 Character Maximum